PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EBIT per Share for the
six
months ended in Dec. 2025 was MAD56.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was MAD109.82.
During the past 12 months, the average EBIT per Share Growth Rate of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM was -10.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -13.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
CAS:PRO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -13.6 Med: -0.2 Max: 24.8
Current: -13.6
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM was 24.80% per year. The lowest was -13.60% per year. And the median was -0.20% per year.
CAS:PRO's 3-Year EBIT Growth Rate is ranked worse than 80.22% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs CAS:PRO: -13.60
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM EBIT per Share Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM EBIT per Share Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD109.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a EBIT per Share of MAD109.82 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #649 out of 809 companies in the Drug Manufacturers industry, placing it in the top 80.2%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EBIT per Share too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current EBIT per Share is MAD109.82. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #649 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #649 out of 809 companies for EBIT per Share. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current EBIT per Share is MAD109.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,328.12, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current EBIT per Share is MAD109.82. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current EBIT per Share is MAD109.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,328.12.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
EBIT per Share: MAD109.82
GF Value™: MAD1,328.12 vs. price of MAD1,349.00 (1.6% above fair value)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score
Get the complete analysis for CAS:PRO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
